CUBT Share Price Performance
US$0.0091
-0.01 (-40.13%)
Price US$0.0091
Share PriceUS$0.0091
CUBT Community Narratives
There are no narratives available yet.
Recent CUBT News & Updates
No updates
Curative Biotechnology, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.0035
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- -62.2%
Curative Biotechnology, Inc. Competitors
About CUBT
- Founded
- n/a
- Employees
- n/a
- CEO
- WebsiteView website
Curative Biotechnology, Inc., a development-stage biomedical company, develops, licenses, and commercializes pharmaceutical products and medical devices for patients with rare diseases. The company develops pipeline focusing on therapeutic areas, such as infectious diseases, oncology, and degenerative eye disease. Its pipeline candidates include Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504 a novel immune therapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a pyrrolobenzodiazepine dimer directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor. The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine. Curative Biotechnology, Inc. is headquartered in Palm Beach Gardens, Florida.
U.S. Market Performance
- 7 Days: -0.2%
- 3 Months: 12.2%
- 1 Year: 22.4%
- Year to Date: 7.7%
In the last week, the market has stayed flat, however the Communication Services sector stood out, gaining 3.4%. As for the longer term, the market has risen 22% in the past 12 months. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading